Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib and Cardiovascular Outcomes in ASCVD Not Adequately Controlled on Maximally Tolerated Lipid-Lowering Therapy
jRCT2031220229Phase 3Active, not recruiting
- Sponsor
- NewAmsterdam Pharma
- Start
- Jul 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia and atherosclerotic disease comparing Obicetrapib 10 mg arm with Placebo arm (2 arms). Primary endpoint: Major Adverse Cardiovascular Events (MACE). Started Jul 2022; status: active, not recruiting.
02
Drugs
obicetrapib
03
Conditions
dyslipidemiaatherosclerotic disease
Beyond the preview
Go deeper on jRCT2031220229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220229.